Related Experiment Video
Updated: Jul 10, 2025
07:25
Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
3.4K
Risk prediction model for mortality in microscopic polyangiitis: multicentre REVEAL cohort study
Takuya Kotani1, Shogo Matsuda2, Ayana Okazaki2
1Department of Internal Medicine (IV), Division of Rheumatology, Osaka Medical and Pharmaceutical University, Daigaku-Machi 2-7, Takatsuki, Osaka, 569-8686, Japan. takuya.kotani@ompu.ac.jp.
Arthritis Research & Therapy
|November 21, 2023
Summary
This study developed a risk prediction model for microscopic polyangiitis (MPA) mortality. Higher Birmingham Vasculitis Activity Score (BVAS) and severe EUVAS classification predict mortality in MPA patients.
Area of Science:
- Rheumatology
- Clinical Epidemiology
- Internal Medicine
Background:
- Microscopic polyangiitis (MPA) is a systemic autoimmune disease requiring accurate mortality risk assessment.
- Existing risk prediction models for MPA may not fully capture the complexity of the disease and its outcomes.
Purpose of the Study:
- To develop refined risk prediction models for mortality in patients with microscopic polyangiitis (MPA).
- To identify comprehensive clinical characteristics that predict mortality in MPA patients.
Main Methods:
- Analysis of data from 194 newly diagnosed MPA patients in the Japanese REVEAL cohort.
- Collection of baseline demographic, clinical, laboratory, and treatment details.
- Univariate and multivariate analyses to identify significant mortality risk factors.
Main Results:
- A total of 60 (30.9%) of 194 patients died during a median follow-up of 202.5 weeks.
- Higher Birmingham Vasculitis Activity Score (BVAS) and severe EUVAS categorization independently predicted mortality.
- A risk prediction model (RPM) stratified patients into low, moderate, and high-risk mortality groups.
Conclusions:
- The developed risk prediction model (RPM) shows promise for predicting mortality in MPA patients.
- This tool can aid clinicians in risk assessment and informed clinical decision-making for MPA management.
